DLK1 and adrenal cortex carcinoma: We then explored the activity of common therapies used to treat ACC in the clinic12 (mitotane, etoposide, doxorubicin, and carboplatin) among two DLK1+ ACC PDOs with and without response to ADCT-701 and PBD (NCI-ACC51 and NCI-ACC48, respectively) that were able to grow in culture longer than other PDOs (greater than 5 passages).